In solid cancers, LAG-3 and PD-1 co-expression has been associated with poor sensitivity to PD-1 blockade and has been proposed as a biomarker for predicting the efficacy of immunotherapy, while data relating to AML are still scarce [129,171,172]. Here, PDCD1 is linked to acute myeloid leukemia.